SAN FRANCISCO (GenomeWeb) – The Mount Sinai Health system this week spun out a new company, Sema4, that will offer the same genetic tests that had been available to patients at Mt. Sinai, but will now do so nationally.

It also plans to expand the testing menu and will look to integrate machine learning and data science to move into predictive medicine, said Eric Schadt, who will serve as CEO of Sema4. Schadt will also maintain a faculty position at Mt. Sinai, as well as an active lab that will collaborate with Sema4 on building predictive models of disease.

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.